Adynamic Bone Disease: From Bone to Vessels in Chronic Kidney Disease
Por:
Bover, J, Urena, P, Brandenburg, V, Goldsmith, D, Ruiz, C, DaSilva, I, Bosch, RJ
Publicada:
1 nov 2014
Resumen:
Adynamic bone disease (ABD) is a well-recognized clinical entity in the complex chronic kidney disease (CKD) mineral and bone disorder. Although the combination of low intact parathyroid hormone (PTH) and low bone alkaline phosphatase levels may be suggestive of ABD, the gold standard for precise diagnosis is histomorphometric analysis of tetracycline double-labeled bone biopsies. ABD essentially is characterized by low bone turnover, low bone volume, normal mineralization, and markedly decreased cellularity with minimal or no fibrosis. ABD is increasing in prevalence relative to other forms of renal osteodystrophy, and is becoming the most frequent type of bone lesion in some series. ABD develops in situations with reduced osteoanabolic stimulation caused by oversuppression of PTH, multifactorial skeletal resistance to PTH actions in uremia, and/or dysregulation of Wnt signaling. All may contribute not only to bone disease but also to the early vascular calcification processes observed in CKD. Various risk factors have been linked to ABD, including calcium loading, ageing, diabetes, hypogonadism, parathyroidectomy, peritoneal dialysis, and antiresorptive therapies, among others. The relationship between low PTH level, ABD, increased risk fracture, and vascular calcifications may at least partially explain the association of ABD with increased mortality rates. To achieve optimal bone and cardiovascular health, attention should be focused not only on classic control of secondary hyperparathyroidism but also on prevention of ABD, especially in the steadily growing proportions of diabetic, white, and elderly patients. Overcoming the insufficient osteoanabolic stimulation in ABD is the ultimate treatment goal. (C) 2014 Elsevier Inc. All rights reserved.
Filiaciones:
Bover, J:
RedinRen, IIB St Pau, Dept Nephrol, Fundacio Puigvert, Barcelona, Catalonia, Spain
Urena, P:
Univ Paris 05, Dept Nephrol & Dialysis, Clin Landy, Dept Renal Physiol,Necker Hosp, Paris, France
Brandenburg, V:
RWTH Univ Hosp, Dept Cardiol & Intens Care Med, Aachen, Germany
Goldsmith, D:
Kings Hlth Partners Acad Hlth Sci Ctr AHSC, London, England
Ruiz, C:
RedinRen, IIB St Pau, Dept Nephrol, Fundacio Puigvert, Barcelona, Catalonia, Spain
DaSilva, I:
RedinRen, IIB St Pau, Dept Nephrol, Fundacio Puigvert, Barcelona, Catalonia, Spain
Bosch, RJ:
RedinRen, IIB St Pau, Dept Nephrol, Fundacio Puigvert, Barcelona, Catalonia, Spain
|